Roy Phillips, MD
Endocrinology, Diabetes & Metabolism · Bel Air, MDNPI 1881699411
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $174,787 of the $208,455 with a category attached, or 83.8%. 45 manufacturers reported payments, led by Lilly USA, LLC at 51.3% of the total. Reporting peaked in 2019 at $89,732 and has fallen 97.7% since, to $2,072 in 2025. Among endocrinology, diabetes & metabolism clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,016 payments — averaging $205.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$107K
- Novo Nordisk$37K
- Amgen$28K
- Boehringer Ingelheim$17K
- Abbott$9K
- AbbVie$5K
- plus $6K from 39 others
What the payments were for
- Consulting fees$6,6253%
- Speaking & faculty fees$174,78784%
- Travel & lodging$9,4715%
- Food & beverage$17,4548%
- Education$1180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$208,455 in reported general payments places this provider in the 95th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
See all endocrinology, diabetes & metabolism providers in Maryland →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 401 | $701,181 |
| JardianceEmpagliflozin | 508 | $673,400 |
| OzempicSemaglutide | 326 | $535,956 |
| JanuviaSitagliptin Phosphate | 257 | $304,804 |
| MounjaroTirzepatide | 121 | $259,673 |
| Tresiba Flextouch U-200Insulin Degludec | 136 | $193,103 |
| FarxigaDapagliflozin Propanediol | 97 | $127,726 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 56 | $122,761 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 74 | $84,364 |
| Tresiba Flextouch U-100Insulin Degludec | 110 | $82,181 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 50 | $76,164 |
| TradjentaLinagliptin | 65 | $74,091 |
| Humalog Kwikpen U-200Insulin Lispro | 44 | $70,158 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 148 | $66,719 |
| Humalog Kwikpen U-100Insulin Lispro | 104 | $52,017 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $106,962 | $969,767546 claims |
| Boehringer IngelheimJardiance, Tradjenta | $17,389 | $747,491573 claims |
| Novo NordiskOzempic, Rybelsus | $36,729 | $570,249344 claims |
| MerckJanuvia, Janumet | $141 | $352,552290 claims |
| AstraZenecaFarxiga | $593 | $127,72697 claims |
| AbbVieSynthroid | $5,042 | $25,902250 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $275 | $6,673522 claims |
| Cequr CorporationCequr Simplicity | $212 | $5,17012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
Other endocrinology, diabetes & metabolism in Bel Air
- Daniel GozziSuitland$1.2M
- Martin SarkarFrederick$1.1M
- Nicholas ArgentoLaurel$1.1M
- Romeu AzevedoCamp Springs$987K
- David BrownRockville$497K
- Philip LevinBaltimore$489K
- Helena RodbardRockville$468K
- Eyob MakonnenAnnapolis$205K
- Jawaad KhokharGlen Burnie$155K
- Adrian DobsBaltimore$149K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.